Article Figures & Data
Figures
- Figure 1
- Sequential CMAPs studies. Serial NCS on weeks 1, 4, and 24 showed gradual recovery of motor DLs; Median nerve: 8.6, 5.7, and 3.4 ms. Ulnar nerve: 5.5, 4.2, and 2.9 ms. Common Peroneal nerve: 10, 9.2, and 5 ms. Also show gradual recovery of CMAP amplitude at weeks 1, 4, and 24; Median nerve: 9.9, 12.7, and 14.8 mv, ulnar nerve: 5.7, 10.4, and 12 mv, common peroneal nerve: 1.6, 4 and 8.3 mv. CMAP - compound muscle action potential. DL - distal latency, ms - milli-second, mv - milli-volt
- Figure 2
- Sequential sensory nerve action potentials studies. Serial NCS on weeks 1,4 and 24 showing mild changes in sensory OLs; Median nerve: 3, 2.4, and 2 ms. Ulnar nerve: 2.2, 2.4, and 2.1 ms. Sural nerve: 3, 3, and 3 ms. But SNAPs amplitude recovery at weeks 1, 4, and 24 was significant in upper limbs; Median nerve: 5, 15, and 36 µv. Ulnar nerve: 13,15 and 44 µv. Sural nerve: 29, 18, and 17 µv. SNAP - sensory nerve action potential. OL - onset latency, ms - milli-second, µv - micro-volt
Tables
Dates 16/07/21 Positive PCR test for COVID-19 virus, a few days after the onset of a feverish illness. 05/08/2021 Presented with a 1-week history of severe sensory symptoms and walking difficulty. NCS results were consistent with a diagnosis of Guillan-Barre Syndrome. 11/8/2021 Admitted to hospital: CSF showed Cyto-albuminologic dissociation consistent with Guillan-Barre Syndrome. Started IV Immunoglobulin 5 days course. 19/8/2021 Follow-up: improved symptoms. 09/09/21 Follow-up: almost full clinical recovery. NCS: showed significant recovery of distal latencies and CMAP amplitude without temporal dispersion, consistent with conduction reversible failure. 28/01/22 NCS: showed almost full recovery of different parameters without temporal dispersion, consistent with conduction reversible failure and probable axonal GBS. NCS - nerve conduction study, CMAPs - compound motor action potentials, GBS - Guillain–Barre syndrome, CSF - Cerebrospinal fluid, PCR - Polymerase chain reaction
